The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

A.R. Artemenko

Sechenov First Moscow State Medical University of (Sechenov University);
LLC «Medical Center «Practical Neurology»

V.G. Abramov

Federal Siberian Scientific and Clinical Center

T.V. Bozhenkina

Federal Siberian Scientific and Clinical Center

Z.N. Konovalova

LLC «Central Institute of Botulinotherapy and Actual Neurology»

A.N. Korenko

LLC «Professorial Clinic «Oda»;
Academian I.P. Pavlov First Saint Petersburg State Medical University

D.A. Krasavina

LLC «Professorial Clinic «Oda»;
Staint Petersburg State Pediatric Medical University

A.L. Kurenkov

LLC «Medical Center «Practical Neurology»;
National Medical Research Center for Children’s Health

N.V. Latysheva

Sechenov First Moscow State Medical University of (Sechenov University);
LLC «Cephalgologist»

M.V. Naprienko

Sechenov First Moscow State Medical University of (Sechenov University);
LLC «Cephalgologist»

O.R. Orlova

Sechenov First Moscow State Medical University of (Sechenov University);
LLC «Central Institute of Botulinotherapy and Actual Neurology»

E.G. Filatova

Sechenov First Moscow State Medical University of (Sechenov University);
LLC «Cephalgologist»

V.S. Shevchenko

LLC «Medical Center «Practical Neurology»;
Treatment and Rehabilitation Center

P.N. Yakovleva

LLC Central Institute of Botulinotherapy and Actual Neurology

Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial

Authors:

A.R. Artemenko, V.G. Abramov, T.V. Bozhenkina, Z.N. Konovalova, A.N. Korenko, D.A. Krasavina, A.L. Kurenkov, N.V. Latysheva, M.V. Naprienko, O.R. Orlova, E.G. Filatova, V.S. Shevchenko, P.N. Yakovleva

More about the authors

Views: 790

Downloaded: 2


To cite this article:

Artemenko AR, Abramov VG, Bozhenkina TV, Konovalova ZN, Korenko AN, Krasavina DA, Kurenkov AL, Latysheva NV, Naprienko MV, Orlova OR, Filatova EG, Shevchenko VS, Yakovleva PN. Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):64‑74. (In Russ.)
https://doi.org/10.17116/jnevro202312311164

Recommended articles:
Reha­bilitation of patients with complications of facial nerve neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(11):90-94
Effi­cacy and safety of Rela­tox for correction of platysmal bands: a clinical trial. Plastic Surgery and Aesthetic Medi­cine. 2023;(3):110-118

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation



We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.